GLP‐1 Mediates the Intrinsic Gut‐Liver Metabolic Signaling in Anti‐VLDL Overproduction and Insulin Resistance in Vagotomized Mice

Perturbations in hepatic lipid and very low density lipoprotein (VLDL) metabolism are involved in the pathogenesis of obesity and hepatic insulin resistance. In this study, our objective was to investigate the intrinsic peripheral gut‐liver vagal nerve circuit in the regulation of hepatic VLDL secretion and insulin sensitivity in sub‐diaphragmatic vagotomized mice. Specifically, by disrupting both hepatic and gastric divisions of the vagal nerve and using fast protein liquid chromatography (FPLC) to subclassify the lipoprotein particles, we discovered that vagotomy significantly decreased triglyceride (TG) contents in VLDL particles compared to that in the control mice with sham‐surgery. Vagotomy further prevented overproduction of VLDL‐TG and VLDL‐apoB induced by an acute fat load. Espousing both sham control and vagotomized mice to a long term high fat diet (HFD) for 22 weeks, we found that vagotomy protected mice from HFD induced hyperlipidemia, obesity, hepatic steatosis and insulin resistance. In an attempt to delineate the molecular mechanism for the anti‐hyperlipidemia and anti‐insulin resistant effect of vagotomy, we investigated the gut hormones and discovered that plasma glucagon‐like peptide‐1(GLP‐1) was significantly higher in the vagotomised mice compared to sham controls, which was associated with significant reduction on mRNA and protein expression of hepatic stearoyl CoA desaturase‐1 (SCD‐1), an enzyme that catalyzes the synthesis of oleyl CoA from stearolyl CoA. In vitro, pre‐treating a rat hepatoma cell line, McA‐7777 cells, with GLP‐1 inhibited SCD‐1 and Fasn mRNA expression which resulted in significant reduction on hepatic de novo lipid synthesis and VLDL secretion. Vagotomy further sensitized insulin sensitivity by upregulating expression of insulin receptors and enhanced activation of downstream signaling molecule, AKT. In conclusion, we demonstrated that increased secretion of GLP‐1 in vagotomized mice mediates the intrinsic gut‐liver metabolic signaling in preventing VLDL overproduction and insulin resistance induced by HFD. GLP‐1 inhibits SCD‐1 activity which in turn inhibits hepatic de novo lipogenesis and VLDL biogenesis. These novel findings, for the first time, provide mechanistic rationale for the application of vagotomy in clinical treatment in patients with obesity and diabetes. Support or Funding Information Hatch Funds from USDA/NIFA to Q. Su